Compare POET & BBOT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | POET | BBOT |
|---|---|---|
| Founded | 1972 | 2016 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 959.0M | 1.1B |
| IPO Year | 2008 | N/A |
| Metric | POET | BBOT |
|---|---|---|
| Price | $6.85 | $9.14 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $24.00 |
| AVG Volume (30 Days) | ★ 6.2M | 237.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $2,939.08 | N/A |
| Revenue Next Year | $710.17 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.10 | $8.70 |
| 52 Week High | $9.41 | $14.87 |
| Indicator | POET | BBOT |
|---|---|---|
| Relative Strength Index (RSI) | 54.76 | 34.72 |
| Support Level | $6.88 | $8.80 |
| Resistance Level | $7.42 | $12.36 |
| Average True Range (ATR) | 0.61 | 0.57 |
| MACD | 0.12 | -0.04 |
| Stochastic Oscillator | 48.31 | 12.39 |
POET Technologies Inc is a design and development company offering high-speed optical engines, light source products, and custom optical modules to the artificial intelligence systems market and hyperscale data centers. Its integration solutions are based on the POET Optical Interposer, a novel, patented platform that allows the seamless integration of electronic and photonic devices into a single chip using wafer-level semiconductor manufacturing techniques. POET's Optical Interposer platform also solves device integration challenges across a broad range of communication, computing, and sensing applications. The company operates geographically in the United States, Canada, Singapore and China.
BridgeBio Oncology Therapeutics Inc, formerly BridgeBio Oncology Therapeutics is a clinical-stage biotechnology company that aims to transform the lives of patients with cancers driven by RAS and PI3Ka, the two frequently mutated oncogenes.